Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses

• Published in: Medicine (Baltimore) Vol. 97; no. 31; p. e11609
• Main Authors: Lomonte, Andrea B V, Radominski, Sebastião C, Marcolino, Flora M D, Brenol, Claiton V, Zerbini, Cristiano A F, García, Erika G, Akylbekova, Ermeg L, Rojo, Ricardo, de Leon, Dario Ponce
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health 01.08.2018
• Subjects: Adult; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - adverse effects; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - drug therapy; Blood Sedimentation - drug effects; Brazil; Clinical Trial/Experimental Study; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinase Inhibitors - administration & dosage; Janus Kinase Inhibitors - adverse effects; Male; Methotrexate - administration & dosage; Methotrexate - adverse effects; Middle Aged; Patient Reported Outcome Measures; Piperidines - administration & dosage; Piperidines - adverse effects; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrroles - administration & dosage; Pyrroles - adverse effects; Treatment Outcome
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000011609

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib in Brazilian patients from Phase 2 (P2) and Phase 3 (P3) global studies of up to 24 months' duration were evaluated. Data were pooled from Brazilian patients with RA and an inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs enrolled in P2/P3 tofacitinib studies who received tofacitinib 5 or 10 mg twice daily (BID), or placebo, as monotherapy or in combination with methotrexate. Efficacy, safety, and patient-reported outcomes were assessed over 24 months. Patients (226) from Brazil were treated in tofacitinib global P2/P3 studies. At Month 3, there were improvements in American College of Rheumatology 20/50/70 response rates, Disease Activity Score in 28 joints, erythrocyte sedimentation rate, and Health Assessment Questionnaire-Disability Index scores with both tofacitinib doses. Improvements from baseline in pain, fatigue, and health-related quality of life with tofacitinib 5 and 10 mg BID were reported. Efficacy improvements were sustained up to Month 24. The most frequent class of adverse events was infections and infestations. No cases of tuberculosis or other opportunistic infections were reported. In a Brazilian subpopulation of patients with RA, tofacitinib reduced disease signs and symptoms and improved physical function up to Month 24, with a safety profile consistent with findings from global studies.